Synthekine company information, Employees & Contact Information

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks Endpoints News

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting BioSpace

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Business Wire

Synthekine’s STK-012 demonstrates potential in solid tumour trial Clinical Trials Arena

Study of SYNCAR-001 and STK-009 Begins in CD19+ Hematologic Malignancies Targeted Oncology

Sanofi partners with Synthekine to develop IL-10 therapeutics Pharmaceutical Technology

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting BioSpace

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class Fierce Biotech

Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies Genetic Engineering and Biotechnology News

Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine MedCity News

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy Frontiers

Naiyer Rizvi named CMO of Synthekine The Cancer Letter

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Business Wire

Synthekine dosed first patient in Phase 1 trial of its IL-2 treatment STK-012 in solid tumors PPF Group

Synthekine scores major $108M B round to secure set of trials in 12 months Fierce Biotech

One of a 'Kine': Synthekine Engineers Cytokine Therapeutics to Treat Cancer and Inflammatory Disease Genetic Engineering and Biotechnology News

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Business Wire

Sanofi pays Synthekine $40M to join preclinical push against vexing inflammatory target Fierce Biotech

Merck and Synthekine Strike $525 Million Cytokine Therapy Deal BioSpace

Where are they now? Catching up with past Fierce 15 honorees Fierce Biotech

Normunity Appoints Debanjan Ray to Board of Directors citybiz

AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions Fierce Biotech

Asher Bio snags $108M series B for immunotherapy programs, push into the clinic Fierce Biotech

AACR 2024: What Cancer Researchers Are Talking About BioSpace